Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants.
Conditions
Interventions
V350A
V350B
+1 more
Locations
9
United States
California Clinical Trials Medical Group managed by PAREXEL ( Site 0011)
Glendale, California, United States
QPS-MRA, LLC ( Site 0012)
Miami, Florida, United States
Alliance for Multispecialty Research, LLC ( Site 0008)
Kansas City, Missouri, United States
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016)
Springfield, Missouri, United States
Velocity Clinical Research Lincoln ( Site 0004)
Lincoln, Nebraska, United States
Velocity Clinical Research, Omaha ( Site 0005)
Omaha, Nebraska, United States
Start Date
December 5, 2024
Primary Completion Date
July 17, 2028
Completion Date
July 17, 2028
Last Updated
April 13, 2026
NCT00104325
NCT07388667
NCT03878121
NCT05447416
NCT01399385
NCT07090785
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions